Uncategorized

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

HUTCHMED Limited announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association Hybrid Congress, taking place on June 13-16, 2024 in Madrid, Spain and …

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress Read More »

El misterio del Mar Mediterráneo seco

En las páginas de la historia de nuestro planeta, hay episodios que desafían nuestra imaginación y nos invitan a explorar los secretos de tiempos pasados. Uno de estos enigmas fascinantes es el período en el que el Mar Mediterráneo se secó, dejando al descub …

Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Seelos Therapeutics, Inc. announced that it has entered into a securities purchase agreement with certain institutional investors, providing for the purchase and sale of 380,968 shares of common stock and pre-funded warrants to purchase up to 81,239 shares of common stock at a price of $2.46 per share in a registered direct offering priced at-the-market …

Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules Read More »

Scroll to Top